Frank Milton Balis

faculty photo
Professor of Pediatrics at the Children's Hospital of Philadelphia
Co-Program Director for Pediatric Oncology, Abramson Cancer Center University of Pennsylvania Philadelphia, PA
Director, Clinical Cancer Research, Center for Childhood Cancer Research The Children's Hospital of Philadelphia Philadelphia, PA
The Louis and Amelia Canuso Family Endowed Chair for Clinical Research in Oncology, The Children's Hospital of Philadelphia Philadelphia, PA
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
3501 Civic Center Blvd., Room CTRB4024
Philadelphia, PA 19104
Office: 267-426-5414
Fax: 267-425-0113
Education:
B.S. (Zoology)
University of North Carolina, 1971.
M.D. (Medicine)
Vanderbilt University, 1975.
Permanent link
 

Description of Itmat Expertise

Drug development for childhood cancers
Clinical pharmacology of anticancer drugs

Description of Research Expertise

Clinical pharmacology of anticancer drugs, cancer biomarkers, clinical trial design

Selected Publications

Balis FM, Womer RB, Berg S, Winick N, Adamson PC, Fox E: Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. Pediatr Blood Cancer ePub, May 2017.

Balis FM, Thompson PA, Mosse YP, Blaney SM, Minard CG, Weigel BJ, Fox E: First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium. Cancer Chemother Pharmacol 79(1): 181-7, Jan 2017.

Vogel J, Lin H, Both S, Tochner Z, Balis F, Hill-Kayser C.: Pencil beam scanning proton therapy for treatment of the retroperitoneum after nephrectomy for Wilms tumor: A dosimetric comparison study. Pediatr Blood Cancer 64(1): 39-45, Jan 2017.

Adamson PC, Balis FM, Bagatell R, Blaney SM: General principles of chemotherapy. Principles and Practice of Pediatric Oncology 6th Ed. Pizzo PA, Adamson PC and Poplack DG (eds.). Lippincott Williams & Wilkins, 2016.

Marachelian A, Desai A, Balis FM, Katzenstein H, Oayed M, Armstrong M, Neville K, Cohn S, Bush M, Gunawan R, Pecha Lim A, Smith M, Smith LM: Comparative pharmacokinetics, safety and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol 77: 405, 2016.

Stieglitz E, Ward AF, Gerbing RB, Alonzo TA, Arceci RJ, Liu YL, Emanuel PD, Widemann BC, Cheng JW, Jayaprakash N, Balis FM, Castleberry RP, Bunin NJ, Loh ML, Cooper TM: Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 62(4): 629-36, Apr 2015.

Fox E, Widemann BC, Pastakia D, Chen CC, Yang SX, Cole D, Balis FM: Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol 76: 1273, 2015.

Barakat LP, Schwartz LA, Reilly A, Deatrick JA, Balis FM: A qualitative study of phase III cancer clinical trial enrollment decision-making: Perspectives from adolescents, young adults, caregivers, and providers. J Adolesc Young Adult Oncol 3: 3, 2014.

Desai A, Fox E, Smith M, Lim A, Maris JM, Balis FM: Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol 2014.

Desai A, Fox E, Smith M, Lim A, Maris JM, Balis FM: Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol 2014.

back to top
Last updated: 07/11/2017
The Trustees of the University of Pennsylvania